News headlines about Kite Pharma (NASDAQ:KITE) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kite Pharma earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.7341715668319 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s rankings:
Shares of Kite Pharma (KITE) traded up $0.20 during mid-day trading on Tuesday, hitting $179.99. 100 shares of the company were exchanged, compared to its average volume of 1,652,408. The stock has a market cap of $10,280.00 and a PE ratio of -26.09. Kite Pharma has a 12 month low of $39.82 and a 12 month high of $179.99.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/16/kite-pharma-kite-given-news-sentiment-score-of-0-22.html.
Kite Pharma Company Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.